Silexion Therapeutics' SIL204 shows promise in treating pancreatic cancer

From GlobeNewswire: 2025-03-05 08:30:00

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced positive data from orthotopic pancreatic cancer models showing SIL204 effectively reduces tumor growth and metastasis in the pancreas. The drug demonstrated significant efficacy across multiple pancreatic cancer cell lines with different KRAS mutation profiles, reducing bioluminescence and tumor cell numbers. This marks a significant advancement in the development program, with potential for treating both primary and metastatic disease. Silexion is actively exploring an expanded development plan for SIL204 using systemic administration, offering hope for patients with difficult-to-treat cancers.



Read more at GlobeNewswire: Silexion Therapeutics Reports Groundbreaking Positive